Swiss multinational healthcare company pioneering pharmaceuticals and diagnostics with focus on oncology, immunology, and infectious diseases.
Profile & Fundamentals
Review the profile, reported financial history, AI financial assessment, dividends, splits, and dated events for Roche Holding.
Profile & Fundamentals
Roche Holding Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Company profile record
Roche Holding AG
Common Stock · Healthcare · Drug Manufacturers - General
Company
- Company / asset
- Roche Holding AG
- Security type
- Common Stock
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- 🇨🇭 Switzerland
- Head office
- Grenzacherstrasse 124, Basel, Switzerland, 4070
Leadership & scale
- Chief executive
- Dr. Thomas Schinecker
- CEO year born
- 1975
- Full-time employees
- 103.2K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- CHF 286.2B
- P/E
- 13.1x
- Revenue (Q2 26)
- CHF 30.4B
- Profit (Q2 26)
- CHF 6.9B
- Dividend Yield
- 1.8%
- Revenue (FY 25)
- CHF 61.5B
- Shares in public float
- 654.1M
- Insider ownership
- 0%
Reporting & identifiers
- Symbol
- ROG.SIX
- Listing
- 🇨🇭 Switzerland | Dividend Tax: 35%
- Ticker Currency
- CHF
- Income Statement Currency
- CHF
- Balance Sheet Currency
- CHF
- Cash Flow Currency
- CHF
- EPS Currency
- CHF
- Contract Type
- SPOT
- ISIN
- CH0012032048
- Asset ID
- equity_73fd14fb-d2e2-59fd-a5e4-45499d17e077
Ownership
Shares Outstanding
Latest: 809.3M | Max: 865.8M | Min: 799.2M
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open every chart, financial statement, event, and source table.